The FDA has approved a subcutaneous version of the Alzheimer’s therapy Leqembi. Called Leqembi IQLIK (lecanemab-irmb), it is a once-weekly subcutaneous autoinjector that is indicated for maintenance dosing (after 18 months of receiving Leqembi IV every two weeks) to treat Alzheimer’s disease (AD) in patients with mild cognitive impairment or mild dementia.

“This shift to subcutaneous maintenance dosing is a crucial step toward making Leqembi more accessible for patients, similar to how diabetes and GLP-1 medications are delivered, and represents the first step towards the day when patients can bypass infusions altogether,” Howard Fillit, M.D., co-founder and chief science officer of the Alzheimer’s Drug Discovery Foundation, said in a news release .

Developed by Eisai and comarketed

See Full Page